Net Income CAGR:16.16%(TTM)
Based on reported financial statement history.
Over longer horizons, Net Income CAGR averages -0.57% over 3 years and 5.11% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Net income CAGR shows how the company's bottom-line profitability has grown. This reflects the company's ability to convert revenue into profits after all expenses.
WST Net Income CAGR Chart
West Pharmaceutical Services, Inc. (WST)
WST Quarterly Net Income Growth (YoY)
Net Income growth vs the same quarter one year earlier, last 20 quarters.
WST Net Income CAGR History
| Year | Start Net Income | End Net Income | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $492.70M | $493.70M | +$1.00M | +0.20% | +0.20% |
| 2024 | $593.40M | $492.70M | $-100.70M | -16.97% | -16.97% |
| 2023 | $585.90M | $593.40M | +$7.50M | +1.28% | +1.28% |
| 2022 | $661.80M | $585.90M | $-75.90M | -11.47% | -11.47% |
| 2021 | $346.20M | $661.80M | +$315.60M | +91.16% | +91.16% |
| 2020 | $241.70M | $346.20M | +$104.50M | +43.24% | +43.24% |
| 2019 | $206.90M | $241.70M | +$34.80M | +16.82% | +16.82% |
| 2018 | $150.70M | $206.90M | +$56.20M | +37.29% | +37.29% |
| 2017 | $143.60M | $150.70M | +$7.10M | +4.94% | +4.94% |
| 2016 | $95.60M | $143.60M | +$48.00M | +50.21% | +50.21% |
| 2015 | $127.10M | $95.60M | $-31.50M | -24.78% | -24.78% |
| 2014 | $112.30M | $127.10M | +$14.80M | +13.18% | +13.18% |
| 2013 | $80.70M | $112.30M | +$31.60M | +39.16% | +39.16% |
| 2012 | $75.50M | $80.70M | +$5.20M | +6.89% | +6.89% |
| 2011 | $65.30M | $75.50M | +$10.20M | +15.62% | +15.62% |
| 2010 | $72.60M | $65.30M | $-7.30M | -10.06% | -10.06% |
| 2009 | $86.00M | $72.60M | $-13.40M | -15.58% | -15.58% |
| 2008 | $70.70M | $86.00M | +$15.30M | +21.64% | +21.64% |
| 2007 | $67.10M | $70.70M | +$3.60M | +5.37% | +5.37% |
| 2006 | $45.60M | $67.10M | +$21.50M | +47.15% | +47.15% |
| 2005 | $19.40M | $45.60M | +$26.20M | +135.05% | +135.05% |
| 2004 | $31.90M | $19.40M | $-12.50M | -39.18% | -39.18% |
| 2003 | $18.40M | $31.90M | +$13.50M | +73.37% | +73.37% |
| 2002 | $-5.20M | $18.40M | +$23.60M | N/A | N/A |
| 2001 | $1.60M | $-5.20M | $-6.80M | -425.00% | N/A |
| 2000 | $38.70M | $1.60M | $-37.10M | -95.87% | -95.87% |
| 1999 | $6.70M | $38.70M | +$32.00M | +477.61% | +477.61% |
| 1998 | $44.40M | $6.70M | $-37.70M | -84.91% | -84.91% |
| 1997 | $16.40M | $44.40M | +$28.00M | +170.73% | +170.73% |
Quarterly Net Income: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $138.80M | +5.1% | +54.6% |
| Q4 2025 | $132.10M | -5.6% | +1.5% |
| Q3 2025 | $140.00M | +6.2% | +2.9% |
| Q2 2025 | $131.80M | +46.8% | +18.4% |
| Q1 2025 | $89.80M | -31.0% | -22.1% |
| Q4 2024 | $130.10M | -4.3% | -5.0% |
| Q3 2024 | $136.00M | +22.2% | -15.7% |
| Q2 2024 | $111.30M | -3.5% | -28.2% |
| Q1 2024 | $115.30M | -15.8% | -17.6% |
| Q4 2023 | $137.00M | -15.1% | +33.0% |
| Q3 2023 | $161.30M | +4.0% | +33.7% |
| Q2 2023 | $155.10M | +10.8% | -17.7% |
| Q1 2023 | $140.00M | +35.9% | -19.4% |
| Q4 2022 | $103.00M | -14.6% | -30.3% |
| Q3 2022 | $120.60M | -36.0% | -31.3% |
| Q2 2022 | $188.50M | +8.5% | +0.6% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Eric Green